Dr Reddy’s Laboratories (RDY) has released an update.
Dr. Reddy’s subsidiary Aurigene Oncology Limited reports positive Phase 1 results for India’s first novel CAR-T cell therapy trial in multiple myeloma patients. The therapy, Ribrecabtagene autoleucel, showed a 100% clinical response rate without any high-grade safety concerns, paving the way for the Phase 2 trial with regulatory approval. These findings could mark a significant advancement in treatment options for Indian myeloma patients.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.
